Pictured: Nasdaq sign on building in New York City/iStock, hapabapa

图为：纽约市纳斯达克登录大厦/哈巴巴帕伊斯托克

As the initial public offering market continues to gather steam in early 2024, California-based Metagenomi on Monday revealed its plans to raise $86.9 million, according to the company’s SEC filing.

根据该公司向美国证券交易委员会提交的文件，随着2024年初首次公开募股市场的持续升温，总部位于加利福尼亚州的Metagenomi周一宣布计划筹资8690万美元。

Metagenomi is looking to sell over six million shares of its stock between $15 and $17 per share on the Nasdaq Exchange with the ticker symbol MGX. The biotech could potentially raise $100.9 million if the underwriters exercise their option to purchase additional shares in full, assuming an IPO price of $16 per share..

Metagenomi希望在纳斯达克交易所以每股15至17美元的价格出售600多万股股票，股票代码为MGX。假设IPO价格为每股16美元，如果承销商行使全额购买额外股份的选择权，该生物技术公司可能会筹集1.009亿美元。。

According to its SEC filing, Metagenomi plans to use the cash it has on hand—around $292.9 million—and the funds raised from the IPO towards several research initiatives, which will provide the company with a cash runway until 2027. The biotech will use $125 million for research and development efforts as well as pre-clinical and proof-of-concept studies for medicines in its pipeline.

根据其向美国证券交易委员会提交的文件，Metagenomi计划将手头约2.929亿美元的现金和IPO筹集的资金用于多项研究计划，这将为该公司提供2027年之前的现金跑道。该生物技术公司将使用1.25亿美元用于研发工作，以及对其正在进行的药物进行临床前和概念验证研究。

Another $85 million will be for IND-enabling studies and two IND filings..

另外8500万美元将用于IND启用研究和两份IND申请。。

Around $75 million will fund the advancement of Metagenomi’s gene editing platform and early-stage research efforts. Another $50 million will go to bolstering manufacturing capabilities to support early-stage efforts. Any funds left over will be used for general corporate purposes.

大约7500万美元将用于推进Metagenomi的基因编辑平台和早期研究工作。另外5000万美元将用于增强制造能力，以支持早期工作。剩下的资金将用于一般公司用途。

“The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our research and development, the status of and results from pre-clinical studies or clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates or strategic opportunities that become available to us, and any unforeseen cash needs,” the SEC filing said.  .

“我们实际支出的金额和时间可能会因多种因素而有很大差异，包括我们的研究和开发进展，我们可能在未来开始的临床前研究或临床试验的状态和结果，以及我们可能与第三方就我们的候选产品或战略机会进行的任何合作美国证券交易委员会（SEC）的文件称：“我们可以使用ome，以及任何不可预见的现金需求。”。。

Metagenomi’s last significant injection of funds came in early 2023 when it received a Series B extension, bringing the amount raised to $275 million with the effort led by Moderna and Bayer. Many of the company’s candidates are in the discovery or pre-clinical stages of development, with a CAR T candidate that has advanced into Phase I.

Metagenomi最后一次大规模注资是在2023年初，当时它获得了B系列的延期，在Moderna和拜耳的带领下，筹集的资金达到2.75亿美元。该公司的许多候选人都处于发现或临床前开发阶段，其中一名CAR T候选人已进入第一阶段。

Metagenomi has also forged partnerships with other major pharma companies including Ionis. .

Metagenomi还与包括Ionis在内的其他主要制药公司建立了合作伙伴关系。。

Metagenomi’s IPO plans come amid a wave of efforts to go public from companies such as Alto Neuroscience, Fractyl Health, ArriVent, and Kyverna.

Metagenomi的IPO计划正值Alto Neuroscience、Fractyl Health、ArriVent和Kyverna等公司纷纷上市之际。

Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

泰勒·帕肯（Tyler Patchen）是BioSpace的一名全职作家。你可以通过tyler.patchen@biospace.com.在LinkedIn上关注他。